A Year at NCI: Harold Varmus Reflects On Provocative Questions, The Duke Scandal, Financial Disaster And Grant Review
Part One Of A Two-Part Interview With NCI Director Harold Varmus
Also: NCCN Committee Reaffirms Clinical Guideline Covering Avastin for Breast Cancer Indication
ODAC Votes For Accelerated Approval For Adcetris For Two Lymphoma Indications
Richard Pazdur’s Comments to ODAC
Department of Defense Offering $16 Million in Cancer Research Grants
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - The Galleri MCD vote: What FDA asked its advisors to ignore
- The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says
